Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DAPAGLIFLOZIN
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
- Dapagliflozin in STEMI Randomized Clinical Trial
- SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
- Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
- To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
- Impact of SGLT2 Inhibitors in Heart Transplant Recipients
- SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
- Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
- The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
- Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets
- The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
- Assessment of Safety and Efficacy of SGLT2is Among LN Patients
- Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
- Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
- Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
- Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
- A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
- SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
- Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)
- GLUcose Transport and REnalPROtection in Chronic Kidney Disease
- Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
- Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
- The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
- Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
- A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Ch
- SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
- Effect of Dapagliflozin on Secondary Mitral Regurgitation
- Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
- Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)
- Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure
- Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy
- Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
- Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
- Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?
- Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
- Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
- Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease
- Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
- The Fontan Dapagliflozin Pilot Study
- Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
- Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
- Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
- Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study.
- Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
- SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
- Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
- Empagliflozin in ESKD - A Feasibility Study
- DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease
- Dapagliflozin, Spironolactone or Both for HFpEF
- Dapagliflozin Therapy In Cardiac Surgery
- Dapagliflozin Effect on Rheumatic Mitral Stenosis
- Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis
- Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
- of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO
- Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
- proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2
- A Study to Assess the Effects of Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
- Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
- Dapagliflozin in Patients With Critical Illness: A Randomized Controlled Trial
- Effect of Dapagliflozin on VT in Patients With Heart Failure.
- Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
- Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
- PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
- Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
- Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
- A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
- Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
- Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury
- A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
- Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
- Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
- Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy
- Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)
- A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients
- Obesity Treatment to Improve Diabetes
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
- Canagliflozin and Myocardial Micro-perfusion
- Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With Chronic Kidney Disease
- The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
- SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients
- Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients
- Pilot Study to Evaluate the Effect of Inflammation in Heart Failure
- DAPAgliflozin for Renal Protection in Heart Transplant Recipients
- Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients
- A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
- Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
- Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- HF Patients With LAVDs Being Treated With SGLT2i
- TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
- Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
- Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
- Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis
- Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
- A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
- Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction
- Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
- Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
- Dapagliflozin in Pulmonary Arterial Hypertension
- Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
- Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy
- Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
- The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure
- Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
- Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg
- To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects
- Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
- The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction
- The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
- Effect of Dietary Magnesium Supplementation vs. Dapagliflozin in Patients With Diabetic Kidney Disease (DKD)
- Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
- Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
- Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
- Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
- Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
- A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
- Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
- The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients
- Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
- CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
- Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
- Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
- A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions
- Dapagliflozin on Volume Vascular Outcomes.
- DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
- A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.
- The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
- Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
- Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
- Dapagliflozin in Non-diabetic Stage IV CKD
- Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
- Effect of Dapagliflozin on LV Remodeling Post AMI
- Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
- Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
- Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
- Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
- EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
- Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF
- Dapagliflozin (DAPA) Effects in HFpEF
- Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
- Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)
- Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
- Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
- Dapagliflozin After Transcatheter Aortic Valve Implantation
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
- SGLT2-Inhibitors for Sleep Apnea in Heart Failure
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
- An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
- Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
- The DAPA-MEMRI Trial
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
- Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®
- Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack
- Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
- Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg
- Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
- Efficacy and Safety of Dapagliflozin in Children With Proteinuria
- Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
- Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
- Empagliflozin and Cardiac Remodelling in People Without Diabetes
- Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
- To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
- Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke
- SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
- The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
- Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
- Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- Dapagliflozin in Respiratory Failure in Patients With COVID-19
- Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
- Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
- Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease
- Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
- Efficacy and Safety of Dapagliflozin in Acute Heart Failure
- DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk
- A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
- Dapagliflozin Heart Failure Readmission
- Renohemodynamic Effects of Combined empagliflOzin and LosARtan
- Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
- The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
- Dapagliflozin Efficacy and Action in PCOS
- The Effects of SGLTi on Diabetic Cardiomyopathy
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
- Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
- Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- A Phase 2b Diabetic Kidney Disease Study
- Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
- Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment
- Dapagliflozin in Physical Exercise in Type 1 Diabetes
- Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
- Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
- SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
- Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.
- Effectiveness of Dapagliflozin for Weight Loss
- Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
- Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
- SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
- Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
- Triple Therapy in T1DM
- Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
- Dapagliflozin Plus Pioglitazone in T1DM
- DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
- DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
- Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial
- A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
- Dapagliflozin In Alzheimer's Disease
- Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF
- Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
- Dapagliflozin Efficacy and Action in NASH
- Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
- Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity
- Dapagliflozin Effects on Hypoglycemia
- Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy
- Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
- Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
- Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
- Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
- Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
- Effect of Dapagliflozin on IAH in T1DM
- Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
- Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
- Dapagliflozin Effect on Erythropoiesis and Physical Fitness
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
- Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease
- A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
- A Phase IV Study in Drug-Naive Patients With T2DM in China
- Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
- Can Exenatide Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
- Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
- Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
- The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
- Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
- Dapagliflozin and Hepatic Glucose Metabolism
- Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
- Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
- Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
- A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co
- PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
- The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
- Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
- Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects
- Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
- A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
- Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
- Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.
- Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension
- Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes
- Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
- Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
- Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
- Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment
- An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
- Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
- Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
- Effect of Anti-diabetic Drugs on Glycemic Variability
- Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery
- Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
- Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
- Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
- Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
- HbA1c Variability in Type II Diabetes
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
- Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
- Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
- Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes
- A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients
- Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
- An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to
- Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
- Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
- Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
- SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
- The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
- Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
- A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2
- Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
- A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
- ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
- Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
- Effect of Dapagliflozin on Inflammation and Endothelial Function
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
- Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
- The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
- The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
- Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)
- Foxiga Korea Local Phase 4 Study
- Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
- Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
- A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With
- Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
- Effect of Dapagliflozine on Systemic and Renal Endothelial Function
- Vildagliptin Versus Dapagliflozin on Glucagon
- Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
- Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
- Effect of Dapagliflozin on Glycemic Variability
- An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
- Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
- Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
- Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Con
- A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
- Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
- Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content
- Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
- Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
- Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
- The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients
- Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes
- Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
- Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
- Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Contr
- A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
- Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
- Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Dapagliflozin Effects on Epicardial Fat
- Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
- Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
- Dapagliflozin in Type 1 Diabetes
- Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
- Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
- Phase III Insulin Add-On Asia Regional Program - ST
- Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
- forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)
- A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
- Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
- Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
- Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
- To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
- PK Study of Dapagliflozin in Pediatric Subjects With T2DM
- BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
- Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
- Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
- Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
- Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
- Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
- Evaluation of Dapagliflozin Taken Twice-daily
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
- Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
- Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
- Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
- A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
- A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose
- Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
- A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
- Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
- Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
- Dapagliflozin DPPIV Inhibitor add-on Study
- Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
- Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
- Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
- Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
- Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
- Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
- Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
- Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
- Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
- Renal Mechanism of Action/Splay vs. TmG
- Effects of Single Oral Dose Dapagliflozin QT Study
- Add-on to Thiazolidinedione (TZD) Failures
- Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
- Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
- Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
- An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
- Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
- Renal Impairment in Type 2 Diabetic Subjects
- Drug Interaction With Metformin
- Phase I Multiple-Ascending Dose (Japan)
- A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
- A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
- A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
- A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
Clinical trials list
click for details